EIGER BIOPHARMACEUTICALS INC (EIGR) Stock Price, Quote, News and Overview
NASDAQ:EIGR - Nasdaq - US28249U2042 - Common Stock - Currency: USD
EIGR Quote, Performance and Key Statistics
1.725
-0.17 (-9.21%)
The current stock price of EIGR is 1.725 USD. In the past month the price decreased by -70.76%. In the past year, price decreased by -94.72%.
EIGR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About EIGR
Company Profile
Eiger BioPharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Palo Alto, California and currently employs 56 full-time employees. The company went IPO on 2014-01-30. Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two therapies in phase III that target critical host processes involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Congenital Hyperinsulinism (HI) and Avexitide in Post-Bariatric Hypoglycemia (PBH). Zokinvy (lonafarnib) for Hutchinson-Gilford progeria syndrome (HGPS) and Processing-Deficient Progeroid Laminopathies (PL) is its approved product. LNF is an orally bioavailable, farnesylation inhibitor in a phase III clinical trial for HDV infection and is its lead program. Lambda is its second program in clinical development for HDV and Covid-19, which is in phase III. Zokinvy is used to reduce the risk of mortality in HGPS and to treat processing-deficient PL.
Company Info
EIGER BIOPHARMACEUTICALS INC
2155 Park Blvd
Palo Alto CALIFORNIA 94306 US
CEO: David A. Cory
Employees: 56
Company Website: https://www.eigerbio.com/
Phone: 16502799845
EIGER BIOPHARMACEUTICALS INC / EIGR FAQ
What is the stock price of EIGER BIOPHARMACEUTICALS INC today?
The current stock price of EIGR is 1.725 USD. The price decreased by -9.21% in the last trading session.
What is the ticker symbol for EIGER BIOPHARMACEUTICALS INC stock?
The exchange symbol of EIGER BIOPHARMACEUTICALS INC is EIGR and it is listed on the Nasdaq exchange.
On which exchange is EIGR stock listed?
EIGR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for EIGER BIOPHARMACEUTICALS INC stock?
8 analysts have analysed EIGR and the average price target is 91.8 USD. This implies a price increase of 5221.74% is expected in the next year compared to the current price of 1.725. Check the EIGER BIOPHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EIGER BIOPHARMACEUTICALS INC worth?
EIGER BIOPHARMACEUTICALS INC (EIGR) has a market capitalization of 2.55M USD. This makes EIGR a Nano Cap stock.
How many employees does EIGER BIOPHARMACEUTICALS INC have?
EIGER BIOPHARMACEUTICALS INC (EIGR) currently has 56 employees.
Is EIGER BIOPHARMACEUTICALS INC (EIGR) expected to grow?
The Revenue of EIGER BIOPHARMACEUTICALS INC (EIGR) is expected to grow by 37.05% in the next year. Check the estimates tab for more information on the EIGR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy EIGER BIOPHARMACEUTICALS INC (EIGR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EIGR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EIGR, evaluating the profitability, health, valuation and growth aspects
- EIGER BIOPHARMACEUTICALS INC (EIGR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EIGER BIOPHARMACEUTICALS INC (EIGR) Sales and EPS estimates to see what analysts future expectations are.
- EIGER BIOPHARMACEUTICALS INC (EIGR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EIGER BIOPHARMACEUTICALS INC (EIGR) Insider and Institutional Ownership to learn about the owners and their transactions.
- EIGER BIOPHARMACEUTICALS INC (EIGR) Stock Chart to make your own analysis
- EIGER BIOPHARMACEUTICALS INC (EIGR) Latest news and press-releases to stay up to date.
Does EIGER BIOPHARMACEUTICALS INC (EIGR) stock pay dividends?
EIGR does not pay a dividend.
What is the Price/Earnings (PE) ratio of EIGER BIOPHARMACEUTICALS INC (EIGR)?
EIGER BIOPHARMACEUTICALS INC (EIGR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-10.49).
EIGR Technical Analysis
EIGR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EIGR. EIGR has a bad profitability rating. Also its financial health evaluation is rather negative.
EIGR Financial Highlights
Over the last trailing twelve months EIGR reported a non-GAAP Earnings per Share(EPS) of -10.49. The EPS decreased by -348.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -193.08% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
EIGR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to EIGR. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 68.29% and a revenue growth 37.05% for EIGR